Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

A*STAR spinout Lucence raises $20M
IHH led a $20 million series A round for Lucence, a blood-based cancer diagnostics company spun out of Singapore’s Agency for Science, Technology and Research (A*STAR) in 2016. The company launched next-generation sequencing test LiquidHALLMARK this year; it is designed to detect cancer-related mutations and cancer-causing viruses. Also participating were SGInnovate, Temasek Holdings’ Heliconia Capital, Lim Kaling, Koh Boon Hwee and other undisclosed investors.

Novo commits $25M to Boston accelerator
Novo Holdings A/S is committing $25 million over five years to seed drug discovery projects at the newly launched Novo Broad Greenhouse, a Boston-based accelerator jointly run by Novo Ventures and the Broad Institute of MIT and Harvard. ...